The Regulation of HIV-1 Transcription: Molecular Targets for Chemotherapeutic Intervention

Miguel Stevens, Erik De Clercq, Jan Balzarini
Rega Institute for Medical Research, Minderbroedersstraat 10, B-3000 Leuven, Belgium
Published online 12 July 2006 in Wiley InterScience (www.interscience.wiley.com).
DOI 10.1002/med.20081

Abstract: The regulation of transcription of the human immunodeficiency virus (HIV) is a complex event that requires the cooperative action of both viral and cellular components. In latently infected resting CD4+ T cells HIV-1 transcription seems to be repressed by deacetylation events mediated by histone deacetylases (HDACs). Upon reactivation of HIV-1 from latency, HDACs are displaced in response to the recruitment of histone acetyltransferases (HATs) by NF-κB or the viral transcriptional activator Tat and result in multiple acetylation events. Following chromatin remodeling of the viral promoter region, transcription is initiated and leads to the formation of the TAR element. The complex of Tat with p-TEFb then binds the loop structures of TAR RNA thereby positioning CDK9 to phosphorylate the cellular RNA polymerase II. The Tat-TAR-dependent phosphorylation of RNA polymerase II plays an important role in transcriptional elongation as well as in other post-transcriptional events. As such, targeting of Tat protein (and/or cellular cofactors) provide an interesting perspective for therapeutic intervention in the HIV replicative cycle and may afford lifetime control of the HIV infection. © 2006 Wiley Periodicals, Inc. Med Res Rev, 26 No. 5, 595–625, 2006

Key words: HIV-1; LTR; transcription; latency; NF-κB; Tat; TAR; RNA polymerase II

1. INTRODUCTION

Acquired immunodeficiency syndrome (AIDS), caused by the human immunodeficiency virus (HIV), remains a global health threat. At present, treatment of HIV-infected individuals is based on combination therapy with HIV-1 reverse transcriptase (RT) and/or protease and/or gp41 inhibitors. Despite the notable success of highly active antiretroviral therapy (HAART) in reducing plasma viral loads to undetectable levels during HIV infection and slowing down clinical progression to AIDS, HAART fails to completely eradicate the virus in HIV-infected individuals. This curative failure is
mainly the result of a small pool of chronically HIV-infected resting CD4+ T cells containing integrated but transcriptionally dormant HIV proviruses to persist. Additionally, emergence of multidrug-resistant viruses have increasingly been reported in patients receiving HAART, urging the need for new anti-HIV treatment strategies. Several targets in the HIV-1 replicative cycle other than RT, protease and virus entry have been identified as possible intervention sites for antiviral chemotherapy. Among these, HIV-1 transcriptional regulation seems to be very attractive, as it would open the possibility to control HIV-1 replication not only in acutely but also in chronically infected cells. In this way, inhibitors of HIV-1 transcriptional regulation may have great potential in anti-HIV drug combination therapy because they can force the virus to slow down its replication rate or even shut-off virus replication and may afford lifetime control of the HIV infection. Moreover, it may be argued that the use of antiretroviral drugs targeted at HIV-1 transcriptional regulation would result in a lower incidence of drug resistance, since the regulation of HIV-1 transcription requires the interplay of both viral and cellular components.

In this review, we will describe the regulation of HIV-1 transcription and identify the viral and cellular components that may serve as potential targets for antiviral chemotherapy.

2. THE HIV-1 PROMOTER

The long terminal repeat (LTR) region of the HIV-1 subtype B genome is divided into three regions which contain four functional domains: the transactivating region (TAR), the basal or core promoter, the enhancer region, and the regulatory elements. The last three are found within U3, whereas the TAR is found within the repeat (R) region (Fig. 1).

Several cellular proteins including Myb,1 Ets-1,2 USF,3 NFAT,4 C/EBP,5 AP-1,6 LEF-1,7 GR,8 RAR,9 and COUP-TF10 have been proposed to interact with the upstream regulatory region capable of up- or downregulating virus expression. For example, within the regulatory domain is a GGTCA palindrome situated to which COUP-TF and RAR, both members of the steroid/thyroid hormone receptor superfamily, bind. Retinoids have been shown to enhance HIV-1 expression through interaction with RAR. Since COUP-TF, a negative regulator of several retinoic acid responsive elements (RAREs), efficiently interact with the same binding site, the retinoid response of the HIV-1 RARE can be significantly repressed.9 Furthermore, synthetic retinoid antagonists are able to inhibit retinoic acid-induced transcriptional activation of the HIV-1 RARE.11 In this way retinoid antagonists could provide an additional way of repressing HIV-1 activation by retinoids in vivo. Another approach for regulation of HIV gene expression, as well as a mechanism for inhibition of viral replication, is the ability of small DNA-binding molecules to target predetermined DNA sequences located within the LTR promoter. Sequence-specific pyrrole-imidazole polyamides have been designed to bind DNA sequences adjacent to recognition sites for the TBP subunit of TFIID, Ets-1, and LEF-1.12 TBP is essential for initiation of HIV-1 transcription, and LEF-1, considered to be an architectural protein, plays a central role in coordinating activities of multiple transcription factors.13 LEF-1 was shown to bend DNA,14 which facilitates protein–protein interactions between transcription factors bound at distant sites, a property which has also been ascribed to the transcription factor USF.15 Both TBP and LEF-1 bind the minor groove of DNA and are likely to be inhibited by the minor groove-binding polyamides. The Ets-1 inhibitory polyamide, on the other hand, not only interferes with the binding of Ets-1 to its recognition helix, but also blocks the formation of the ternary Ets-1 NF-κB DNA complex at the HIV-1 enhancer. This ternary complex formation can also be inhibited by polyamides which bind adjacent to the recognition sites for NF-κB.16

The HIV-1 enhancer region consists of two tandem binding sites for the transcription factor NF-κB. The AP-2 transcription factor binds between these two NF-κB motifs and has positive
Figure 1. Structure of the HIV genome and the viral promoter elements. The 5' LTR promoter consists of three structural sequence elements, U3 (nt −453 to −3), R (nt +1 to +98), and U5 (nt +99 to +180) with +1 as the start site of transcription and four main functional domains: a regulatory region (nt −454 to −104), an enhancer element (nt −105 to −79), a core promoter (nt −78 to −1), and a TAR element (nt +1 to +60). Within the TAR element two initiator elements (InR) are located from −3 to +8 and +35 to +59, and an inducer of short transcripts (IST) spans the initiation region from positions −5 through +26 and +40 through +59. Regardless the site of integration, the 5' LTR promoter of HIV is packaged by two nucleosomes, nuc-0, which is located between nucleotides −415 and −255, and nuc-1, which is located between nucleotides +10 and +155. The 5' LTR promoter incorporates several cis-acting DNA sequences for binding cellular transcription factors including COUP, chicken ovalbumin upstream promoter transcription factor; RAR, retinoic acid receptor; Myb, Myb binding protein; NFAT, nuclear factor of activated T cells; USF, upstream stimulating factor; Ets, Ets binding factor; LEF-1, lymphocyte enhancer factor; C/EBP, CCAAT/enhancer binding protein; NF-kB, nuclear factor kappa B; AP-2, activator protein 2; SP-1, SP1 binding protein; TFIID, transcription factor IID; LSF, late SV40 transcription factor; TDP-43, TAR DNA-binding protein; FBI-1, factor that binds to IST; CTF/NF1, CAAT-box transcription factor/nuclear factor 1; AP-1, activator protein 1; IRF, interferon regulatory factors.
effects on the transcriptional level without interfering with the NF-κB-mediated TNF-α induction.17

The core promoter region resembles that of many eukaryotic genes transcribed by the RNA polymerase II. In general, core promoters comprise either a TATA box or the initiator region (InR), a pyrimidine-rich site that spans the RNA start. The HIV-1 core promoter contains both type of elements though with a TATA motif that starts 2 nucleotides further upstream (CATATA box).18 General transcription factors are able to bind both type of elements, in addition with three tandem-repeat Sp1 binding sites.19 Numerous cellular factors interact extensively with this region and seem to play an important role in the assembly of a preinitiation complex (PIC) and in the transcriptional regulation of the viral promoter. A cellular DNA-binding protein, LSF (also known as LBP-1 or UBP), sequentially interacts in a concentration-dependent manner with two sites that surround the transcriptional initiation site of the HIV-1 promoter. Although sequences in the downstream site overlapping the InR were found to enhance transcription, purified LSF specifically repressed HIV transcription by binding to the upstream site which overlaps the TATA box element, preventing the TFIID complex to bind the promoter.20 Furthermore, this cellular factor is able to restrict the elongation of HIV-1 transcripts after PIC formation suggesting that LSF could be part of a mechanism that blocks transcription processivity.21 The mechanism by which LSF represses HIV-1 transcription involves the transcriptional regulator YY1. A unique cooperation of both cellular factors seems to specifically synergize negative regulation of HIV-1 LTR expression.22 The transcriptional repression caused by YY1 leads to the recruitment of histone deacetylase (HDAC1), maintaining the nucleosome nuc-1 in a deacetylated state.23,24 This kind of potent repression of LTR transcription could allow an activated, HIV-infected cell to return to a dormant state and establish a stable non-productive infection. In addition, it was possible to counteract the repression by targeting DNA sequences adjacent to recognition sites for LSF with pyrrole-imidazole polyamides25 or by inhibition of the mitogen-activated protein kinase (MAPK) p38 that regulates LSF binding to the LTR promoter.26 Other cellular factors associated with the core promoter are TDP-43 and USF. TDP-43 has been shown to bind to the InR and is capable of modulating HIV-1 gene expression by either altering or blocking the assembly of transcription complexes either in the presence or absence of Tat.27 On the other hand, USF showed a stimulatory effect on the transcriptional machinery.28 Within the core promoter an unusual transcriptional element is located just downstream of the start site of transcription and is known as the inducer of short transcripts or IST. This bipartite DNA element promotes the synthesis of short transcripts via formation of transcription complexes that are unable to elongate efficiently.29 Factor binding to IST (FBI-1) binds specifically to this IST element suggesting a role in the establishment of these abortive transcription complexes.30

The RNA element TAR, which is encoded largely between the two IST half-elements, forms a stable secondary stem-loop structure and represents a key element in the Tat-mediated transcriptional activation (vide infra).

Finally, the 5′-untranslated leader region (5′-UTR) also contains important transcriptional elements for transcription factors such as AP-1, NF-κB, NF-AT, IRF, and Sp1.31,32 IRF-1 is able to significantly increase the basal transcriptional activity of the HIV-1 LTR promoter by recruiting the acetyltransferase CBP.33,34 Consistent with this, only IRF-1 and IRF-2 bind the ISRE-like element on the HIV-1 LTR.35

3. TRANSCRIPTIONAL STIMULATION

The transcription factor NF-κB was found to be activated in many cell types in response to a broad range of stimuli and conditions.36 Previously, it has been proposed that diverse stimuli all act through a common step involving an increase in oxidative stress within the cell. Evidence for
HIV-1 TRANSCRIPTION AS TARGET FOR CHEMOTHERAPY

this oxidative stress response, defined as an increase in intracellular ROS, stemmed from in the induction of the expression and replication of HIV-1 by H$_2$O$_2$, and the inhibition of the NF-$\kappa$B signaling pathway by antioxidants such as pyrrolidine dithiocarbamate (PDTC) and N-acetyl-L-cysteine (NAC). These effects seem to be cell or stimulus specific, suggesting that this oxidative stress model in NF-$\kappa$B activation is an exception rather than the rule.

Hence, stimulation with tumor necrosis factor alpha (TNF-$\alpha$) or phorbol 12-myristate 13-acetate (PMA) decreased intracellular thiol levels, an observation that could be counteracted by NAC. Since then, more evidence appeared for a role of thiols within the cell, indicating that NF-$\kappa$B activity must be regulated in a redox modulatory way dependent on the intracellular thiol levels.

NF-$\kappa$B exists in the cytoplasm of unstimulated cells as a latent form of a transcriptionally active p50/p65 dimer bound to an inhibitory protein, IxB$\alpha$ (Fig. 2). Activation of NF-$\kappa$B involves the phosphorylation of IxB$\alpha$ at two serine residues (S32 and S36) by the IKK complex, which targets the inhibitor protein for ubiquitination and subsequent degradation by the 26S proteasome. In addition to the phosphorylation of IxB$\alpha$, the IKK complex also phosphorylates the p65 subunit of NF-$\kappa$B on serine 536 in the transactivation domain controlling the kinetics of the p65 nuclear import and cytosolic IxB$\alpha$ localization. PDTC and NAC have been shown to prevent the phosphorylation of IxB$\alpha$ which may account for their inhibition of NF-$\kappa$B activity. As a result of this finding, various antioxidants have been examined for their inhibitory effects on HIV-1 activation. In this way, compounds such as a-lipoic acid, oltipraz, $\alpha$-tocopherol (vitamin E), and butylated hydroxyanisole (BHA) were found to inhibit HIV-1 LTR-directed gene expression and to suppress viral replication (Table I and Fig. 5). In addition to antioxidants, other compounds such as salicylates or aspirin-like drugs, pentoxifylline, coumarins, acridone derivatives, iron chelators, and the binding subunit of pertussis toxin were also found to be inhibitory to NF-$\kappa$B activation.

Upon release of IxB$\alpha$, the nuclear localization signal (NLS) on the p65 subunit becomes unmasked, which allows for a rapid translocation of NF-$\kappa$B to the nucleus. Importantly, the p65 subunit becomes phosphorylated on serine 276 by protein kinase A (PKA) rendering NF-$\kappa$B transcriptional active through recruitment of the histone acetyltransferase p300/CBP to the viral promoter. It is known that p50 homodimers are also phosphorylated by PKA and associate with HDAC-1 in unstimulated cells to bind to the viral promoter and cause a transcriptional repression. However, NF-$\kappa$B p50/p65 heterodimers bind with greater affinity to the promoter enabling signal-induced heterodimers to displace p50-HDAC-1 from the promoter and activate transcription. As unphosphorylated p65 also interacts with HDAC-1, the phosphorylation of nuclear NF-$\kappa$B determines whether it associates with p300/CBP or HDAC-1, ensuring that only signal-induced NF-$\kappa$B entering the nucleus can activate transcription. Once in the nucleus, a cellular reducing catalyst thioredoxin plays a major role in the stimulation of the DNA binding of NF-$\kappa$B by reduction of a disulphide bond involving cysteine 62 on the p50 subunit. This selective reduction of the oxidized p50 subunit is also mediated by the nuclear signaling protein redox factor-1 (Ref-1). Both factors TRX and Ref-1 are not only required for NF-$\kappa$B binding but can also interact with each other to stimulate the DNA-binding activity of AP-1. Although the activation of NF-$\kappa$B have been shown to occur under oxidative conditions through the release and degradation of IxB$\alpha$, the binding of NF-$\kappa$B to the LTR promoter seems to be dependent on reducing conditions. It is likely that various compounds may impair this NF-$\kappa$B DNA-binding activity and, as a result, inhibit LTR-driven gene expression. In this way, some cell systems showed that the effects of PDTC on NF-$\kappa$B were not primarily due to its antioxidant properties, but could be ascribed to a pro-oxidant effect of PDTC through a mechanism involving a shift towards oxidizing conditions. This observation supports the previous conclusion that the effects of antioxidants on NF-$\kappa$B activation are cell or stimulus dependent. The NF-$\kappa$B DNA binding impairment was also true not only for the oxidizing agent diamide, but also for the alkylating agent, N-ethylmaleimide and the pyridine N-oxide derivatives. The oxidizing properties of these compounds can be reversed by treatment with $\beta$-mercaptoethanol, which provides reducing conditions for thiol components. The antiviral effects of nitric oxide (NO)
mediated through NF-κB inhibition have been demonstrated with the use of NO-generating agents such as S-nitroso-N-acetylpenicillamine (SNAP) and sodium nitroprusside (SNP). Although NO production is increased in HIV-1-infected patients, this free radical seems to inhibit the NF-κB signaling pathway at multiple levels, that is, at the activation level as well as the DNA-binding level. Other compounds such as cepharamine, hydroxyurea, and carboxamidotriazole also target the NF-κB signaling pathway, but the molecular basis of their antiviral activity remains to be determined.

4. TRANSCRIPTIONAL ACTIVATION

The HIV-1 provirus is packaged into chromatin whereby, independently of the site of integration, nucleosomes are positioned precisely on the 5'-LTR promoter region with respect to cis-acting regulatory elements. This higher ordered chromatin structure negatively regulates gene expression by restricting access of the transcriptional machinery to the viral promoter. Multiprotein complexes bind the viral promoter to induce a nucleosomal rearrangement in such a way that DNA regulatory sequences become more accessible to other sequence-specific proteins. As a result, these changes frequently are identified as an increase in sensitivity at specific DNA sequences to digestion by the nuclease DNase I, and are, therefore, termed DNase I-hypersensitive sites (DHSs).

Two nucleosomes (called nuc-0 and nuc-1) are positioned within the viral promoter. Nuc-0 is positioned upstream of the modulatory region whereas nuc-1 is immediately downstream of the viral transcription start site (Fig. 1). These nucleosomes define two open regions, one encompassing the regulatory region plus the enhancer/core promoter region (nt 200–465), whereas the other region contains regulatory elements in the 5'-UTR downstream of the transcription start site (nt 610–720). Importantly, upon stimulation with phorbol esters, TNF-α or histone deacetylase inhibitors, nuc-1 becomes rapidly and specifically disrupted by acetylation of specific lysine residues within histone H3 and H4 of nuc-1. This nucleosomal remodeling, which is insensitive to the transcription inhibitor α-amanitin, results in an open nucleosome-free region from nt 200 to nt 720 leading to a marked increase in sensitivity to DNase I. Nuc-1 disruption is necessary for transcriptional activation as it blocks the binding of transcription factors necessary for the assembly of a PIC and cause an arrest in the progression of RNA polymerase II (RNAPII), resulting in inefficient elongation and the accumulation of short attenuated transcripts. Since nuc-1 is the only disrupted nucleosome in the HIV-1 promoter after global hyperacetylation due to histone acetylase inhibitors, suggests that an additional level of specificity must exist in this system. This may be mediated through a displacement of corepressor complexes containing HDAC, which has been recruited to the viral promoter by host factors such as LSF with YY1 and the NF-κB p50

Figure 2. NF-κB transcriptional activation can be considered as two distinct steps with respect to the cellular compartment. One step involves the phosphorylation and subsequent degradation of IkB in the cytoplasm followed by the nuclear translocation of the active transcription factor. Another step is the DNA binding of the cellular transcription factor resulting in transcriptional activation of the viral genome in the nucleus. Upon stimulation IkB is phosphorylated by the IkB kinase complex (IKK), containing IKKα/IKKγ, Ubiquitination and degradation of IkBα by the 26S proteasome complex activates PKA that phosphorylates the NF-κB p65 subunit at Ser276 rendering NF-κB transcriptionally active through recruitment of p300/CREB. In addition to the release of IkBα, the nuclear localization signal (NLS) on the p65 subunit becomes unmasked, which allows for a rapid translocation of NF-κB to the nucleus and acetylation of p65 on Lys221 by p300/CREB. Once in the nucleus, a disulfide bond involving cysteine 62 on the p50 subunit of the NF-κB p50/p65 heterodimers becomes reduced by TRX and Ref-1, and allows for a rapid displacement of the Ser373-phosphorylated p50 homodimers associated with HDAC-1, which repress transcription. Transcriptional activation involves not only the viral genome but a wide variety of genes, including that of its own inhibitor IkBα. As the new synthesized IkBα enters the nucleus and removes NF-κB from the viral promoter to transport it back to the cytoplasm leading to the termination of the NF-κB-dependent transcription. In order to terminate the NF-κB transcriptional response, the p65 subunit of the NF-κB p50/p65 heterodimer must become deacetylated by HDAC-3 which allows the binding of deacetylated p65 to newly synthesized IkBα proteins induced by NF-κB.
Figure 2.

HIV-1 TRANSCRIPTION AS TARGET FOR CHEMOTHERAPY
homodimers, in response to the recruitment of chromatin remodeling and modifying complexes by NF-kB p50/p65 heterodimers (or Tat) (Fig. 3A and B). The association of NF-kB to a coactivator complex containing p300/CREB but possibly also p300/CREB-associated factor (P/CAF), steroid receptor coactivator-1 (SRC-1), and SRC-1-related proteins, not only results in the disruption of nucleosome-1, but may also lead to an increase in stability of the activator–DNA complex and to an increase in accessibility of promoter sequences for binding transcription factors and regulatory proteins indispensable for stimulation of the transcription initiation process.83–85

An important consequence of histone acetylation appears to be the recruitment of the ATP-dependent chromatin remodeling complex SWI/SNF to the LTR promoter.86 More specifically, the ATPase subunit of the SWI/SNF chromatin remodeling complex Brahma-related gene 1 (BRG-1) is recruited to the AP1-3 site located at the 3'-end of nucleosome-1. This event seems to be mediated by an inducible factor ATF-3 (with JunB as a possible dimerization partner) in the presence of HMGA1 proteins. Although ATF-3 and HMGA1 confer the specificity of recruiting SWI/SNF to nucleosome-1, histone acetylation stabilizes the interaction of the complex at the edge of nucleosome-1.87,88 In other words, during HIV-1 transcriptional activation histone acetylation acts as a signal for the recruitment of chromatin remodeling complexes. Upon interaction with nucleosome-1, SWI/SNF utilizes the energy from ATP hydrolysis to disrupt nucleosome-1 in a non-covalent manner. The exact mechanism by which SWI/SNF disrupts the histone–DNA interactions to facilitate transcription is yet not clear, but it is believed to either slide the DNA helix in a screw-like manner or to propagate a DNA bulge around the nucleosome interface.89,90 Retinoic acid inhibits HIV-1 transcriptional activation by interfering with nucleosome-1 remodeling without affecting histone acetylation.91

5. TRANSCRIPTIONAL MACHINERY

The synthesis of mature and functional HIV messenger RNA or transcription is a complex, multistage process that requires the cooperative action of viral and cellular proteins (Fig. 3C and D). At the initiation of transcription, the TATA box is recognized by the TBP. The binding of TBP usually
Figure 3.
initiates a cascade of additional interactions with different proteins, also referred as the TBP-associated factors (TAF), to assemble as a multisubunit TFIID complex. Once TFIID is formed, additional multicomponent transcription factors are recruited including TFIIA, TFIIB, TFIIE, TFIIF, and TFIIF into a PIC. Within the assembly of the PIC a multisubunit enzyme, RNA polymerase II (RNAPII), is found that catalyzes the synthesis of viral mRNA from the proviral DNA. The largest subunit of RNAPII is unique in that it contains a carboxyl-terminal domain (CTD) consisting of multiple-tandem repeats of the YSPTSPS heptapeptide, with both Ser2 and Ser5 the sites of reversible phosphorylation. Although the viral transcriptional activator Tat and its cellular cofactor p-TEFb are mainly ascribed to the transcription elongation step (vide infra), recent evidence points towards a role of both proteins in transcription initiation. Tat and p-TEFb facilitate the binding of TBP to the transcription complex enabling the assembly of the PIC.

Once the PIC assembly is complete, TFIIF performs at least three critical functions in RNAPII transcription: (1) it mediates ATP-dependent strand separation through its 3'-5' helicase activity at the transcription start site, resulting in an open DNA complex from positions −9 to +2,96,97 (2) it phosphorylates the fifth serine of the heptapeptide repeat present in the CTD of RNAPII through its CDK7 kinase subunit during the transition from transcription initiation complex to a stable elongation complex,98,99 and (3) it suppresses transcription arrest of early RNAPII elongation intermediates.100,101 Although CTD phosphorylation is temporally correlated with promoter clearance and thought to be a prerequisite for the formation of a stable elongation complex, the precise role of CTD phosphorylation remains obscure. The idea that phosphorylation of the CTD at multiple sites serves to disrupt interactions between the unmodified CTD and proteins necessary for the formation of a stable PIC remains an attractive possibility. Not only TFIIF, but also the p65 subunit of the transcriptional activator NF-κB, was thought to influence RNAPII processivity. In this way, NF-κB was able to stimulate transcriptional elongation probably due to the recruitment of the CTD kinase, p-TEFb, which catalyzes the phosphorylation of the second serine of the heptapeptide repeat present in the CTD of RNAPII.102,103 The phosphorylation pattern changes during the transcription cycle resulting in the recruitment of specific mRNA-processing factors. CTD phosphorylation on Ser5 must occur during the transition from transcription initiation to elongation, because phosphorylated CTD has a role in recruiting mRNA capping guanylyltransferase enzymes to the nascent transcript, and 5'-mRNA capping occurs soon after promoter clearance.104,105 Furthermore, CTD phosphorylation on Ser2 triggers binding of the splicing and the 3'-mRNA processing machinery, and recruits specific factors involved in transcription termination.106,107

Following promoter clearance, and before entering productive elongation, the processivity of RNAPII is controlled by the action of both negative and positive elongation factors (N-TEFs and P-TEFs).108,109 Negative elongation factors (NELF), such as the DRB (5,6-dichloro-1-β-D-ribofuranosylbenzimidazole) sensitivity-inducing factor (DSIF, a human homolog of yeast Spt4–Spt5 complex) and the NELF, have been proposed to be responsible for premature stopping and termination of the initiated polymerase, resulting in the generation of short abortive transcripts. NELF acts cooperatively with DSIF through binding to the DSIF/RNAPII complex and to nascent transcripts.110 On the other hand, positive elongation factors, such as p-TEFb, are known to mediate the transition from abortive into a productive elongation complex by phosphorylating the RNAPII CTD.111,112 p-TEFb is composed of two subunits: the catalytic subunit cyclin-dependent kinase CDK9 (previously named PITALRE) and the regulatory subunit cyclin T1. The exact mechanism by which DSIF, NELF, and p-TEFb act together is still unclear, but evidence suggests that DSIF and NELF negatively regulate elongation through interactions with RNAPII containing a hypophosphorylated CTD. Phosphorylation of the RNAPII CTD, the hSpt5 subunit of DSIF, and the NELF by p-TEFb might overcome the repression and promote elongation.113,114

Upon promoter clearance, the interaction between the hyperphosphorylated RNAPII and TFIIB, TFIIE, TFIIF, and TFIIF must be broken to engender a fully competent transcriptional apparatus. During elongation, TFIID can remain bound to the core promoter supporting reinitiation of
transcription by RNAPII and the other transcription factors. However, since the dephosphorylated form of RNAPII preferentially enters the PIC, recycling of this enzyme is necessary and is likely to be mediated by a serine/threonine TFIIF-associated CTD phosphatase (FCP1). This RNAPII recycling process seems to be stimulated by TFIIF (RAP74), which is plausible as TFIIF is known to directly interact with RNAPII and to play a role in the recruitment of RNAPII to the PIC. Alternatively, small CTD phosphatase (SCP1) activity is also enhanced by TFIIF (RAP74) with preferential dephosphorylation of RNAPII on Ser5, whereas FCP1 dephosphorylates Ser2 and Ser5 with comparable efficiency. Efficient reinitiation of transcription can be achieved if recycled RNAPII re-enters the PIC before TFIID dissociates from the core promoter.

6. TAT-ACTIVATED TRANSCRIPTION

The HIV-1 promoter directs the synthesis of two classes of RNA molecules, short non-polyadenylated transcripts, and full-length polyadenylated transcripts. In the absence of the viral transcriptional activator Tat, efficient synthesis of the short transcripts is dependent on the IST and corresponds to RNAs with heterogeneous 3′ ends located around positions +59 that contain the TAR element, the binding site for Tat. In the presence of Tat, the amount of short transcripts is decreased while the synthesis of full-length transcripts are dramatically increased. Thus, IST seems to stimulate the formation of abortive transcription elongation complexes so as to synthesize the binding site necessary for Tat function. A cellular POZ (for poxvirus and zinc fingers) domain containing factor FBI-1, binds specifically to this IST suggesting a role in the formation of the HIV-1 short transcripts. In addition, FBI-1 associates to, and stimulates Tat, implicating that repression of the short transcripts by Tat may be mediated through interactions between these two factors.

A. Tat–TAR Interaction

The TAR element, encoded largely between the two IST half-elements, forms a highly stable, nuclease-resistant, secondary stem-loop structure, and is directly bound by the Tat protein (Fig. 4). Tat recognition of TAR involves the presence of a pyrimidine-rich bulge near the apex of the TAR RNA stem and nucleotide pairs flanking the bulge (G21:C41 and A22:U40::G26:C39 and A27:U38). Analysis of compensatory mutations in the TAR RNA stem reveals that the primary nucleotide sequence throughout the TAR stem does not appear to be a prerequisite for Tat recognition. However, TAR RNA mutations that affect base-paring and, hence, the secondary structure of the pyrimidine-rich bulge, abolish Tat activity. NMR studies have revealed that, in order to obtain an effective Tat–TAR interaction, Tat recognition requires conformational changes within the TAR RNA structure. This rearrangement process involves the displacement of the first residue in the bulge (U23) by one of the arginine side chains present in the basic binding domain of the Tat protein. The displaced U23 is brought into close proximity with G26 creating an arginine binding pocket and enabling TAR RNA to undergo a transition from a structure with an open and accessible major groove to a much more rigid structure. In addition, the conformational change also repositions critical phosphates on the TAR RNA backbone that can be easily contacted by other basic residues found in the TAR RNA-binding region. These contacts contribute not only to the affinity of the Tat–TAR interaction, but also to its specificity, by providing discrimination with respect to other bulged RNA structures. Different anti-HIV approaches were developed through interference with the Tat–TAR interaction, including the synthesis of peptoids (such as CGP64222 or TR87), Tat peptide mimetics, quinolone derivatives, polyanamide oligomers, arginine-aminoglycoside conjugates, intercalators, chemically modified RNA aptamers, or TAR RNA decoys (Table I and Fig. 5). Other approaches that sequester Tat’s function were based on the development of small interfering RNAs (siRNAs) directed against Tat expression, the discovery of granulins that
Figure 4. A model for the regulation of Tat-mediated transcription. Initially, non-acetylated Tat interacts with P/CAF which was found to be associated with the HIV-1 promoter only in response to Tat. P/CAF acetylates Tat at position Lys28. This subsequently abrogates the interaction between P/CAF and Tat, but significantly enhances its interaction with p-TEFb which is released from its association with MAO1/HEXIM1 and 7SK snRNA upon different stimuli including stress, ultraviolet light, DRB, and hypertrophic signals. The complex of Tat with autophosphorylated p-TEFb then binds the upper bulge and loop structures of TAR, thereby positioning CDK9 to phosphorylate also the negative elongation factors NELF and DSIF, which repress transcription by binding to the lower stem in TAR, as well as the CTD of RNAPII on both Ser2 and Ser5. These phosphorylation events result in the release of the transcriptional elongation block. In addition to the productive elongation mediated by the hyperphosphorylated RNAPII, Tat becomes acetylated by p300/CREB on Lys50 resulting in the dissociation of p-TEFb-Tat from TAR RNA and subsequent binding to the elongating RNAPII. Furthermore, the acetylation of Tat on Lys50 serves as a signal to recruit P/CAF generating a p-TEFb-Tat-P/CAF ternary complex associated with RNAPII during transcriptional elongation.
Table I. Overview of the HIV-1 Transcription Inhibitors with Their Target for Chemotherapeutic Intervention

| Inhibitor                        | Molecular target            | Reference |
|----------------------------------|-----------------------------|-----------|
| PDTC                             | NF-κB activation            | 38, 45    |
| NAC                              | NF-κB activation            | 39, 45    |
| α-lipoic acid                    | NF-κB activation            | 46, 47    |
| Oltipraz                         | NF-κB activation            | 48, 49    |
| α-tocopherol                     | NF-κB activation            | 50        |
| BHA                              | NF-κB activation            | 50        |
| Salicylates                      | NF-κB activation            | 51        |
| Pentoxifylline                   | NF-κB activation            | 52, 53    |
| Coumarins                        | NF-κB activation            | 54        |
| Acridone derivatives            | NF-κB activation            | 55        |
| Iron chelators                   | NF-κB activation            | 56, 57    |
| B-oligomer of pertussis toxin    | NF-κB activation            | 58, 59    |
| Diamide                          | NF-κB binding               | 72        |
| N-ethylmaleimide                 | NF-κB binding               | 72        |
| Pyridine N-oxide derivatives     | NF-κB binding               | 73        |
| Cepharanthine                    | NF-κB signalling pathway    | 75        |
| Hydroxyurea                      | NF-κB signalling pathway    | 76        |
| Carboxyamidotriazole             | NF-κB signalling pathway    | 77        |
| All-trans retinoic acid          | Nuc-1 remodeling            | 91        |
| CGP64222                         | Tat-TAR interaction         | 133       |
| TR87                             | Tat-TAR interaction         | 134       |
| Tat peptide mimetics             | Tat-TAR interaction         | 135       |
| Quinolone derivatives            | Tat-TAR interaction         | 136, 137  |
| Arginine-aminoglycoside conjugates| Tat-TAR interaction       | 139       |
| Intercalators                    | Tat-TAR interaction         | 140       |
| RNA aptamers                     | Tat-TAR interaction         | 141, 142  |
| TAR RNA decoys                   | Tat-TAR interaction         | 143, 144, 145 |
| Granulins                        | Tat or p-TEFb               | 147, 148  |
| Flavopiridol                     | p-TEFb                      | 187       |
| R-roscovitine                    | p-TEFb                      | 188, 189  |
| Curcumin                         | p300/CBP                    | 224, 225  |
| HR73                             | SIRT1                       | 226       |
Figure 5. Chemical structures of the HIV-1 transcription inhibitors.
Figure 5. (Continued)
Figure 5. (Continued)
HIV-1 TRANSCRIPTION AS TARGET FOR CHEMOTHERAPY

Intercalators

RBT418

RBT550

Roscovitine

Flavopiridol

HR73

Curcumin

Figure 5. (Continued)
bind directly to Tat or hCycT1, and the introduction of antibodies directed to Tat or hCycT1.

The HIV-1 trans-activator protein Tat is a small polypeptide (101 amino acids in most clinical HIV-1 isolates; 86 amino acids in the laboratory strain HIV-1\textsubscript{HXB2}) encoded from two separate exons and is essential for efficient transcription of the viral genome. In the first exon (amino acids 1–72) there is an N-terminal proline-rich/acidic region (amino acids 1–21), a region containing seven cysteines (amino acids 22–37), a core region (amino acids 38–48), and a basic region enriched with arginine and lysine amino acids that is highly conserved among different strains (amino acids 49–57). The second exon starts at amino acid position 73 and has a more variable sequence. Based on mutational analysis, Tat can be divided into two functional domains. The first domain is the functionally autonomous transcription-activation domain (amino acids 1–48), which may be involved in metal ion binding. The second functional domain comprises the complete basic region (amino acids 49–57), which is essential for TAR RNA binding and functions as a NLS for Tat. Furthermore, it appears that the basic domain of Tat is also important for translocation through the cell membrane. It is quite unusual that Tat is able to leave the cell and enter adjacent cells without any loss of transcriptional activity. Although the precise mechanism by which this unique biological property occurs has not been clarified yet, it offers major possibilities for drug delivery as it would allow it to translocate less permeable molecules into the cell. Other pleiotropic activities of extracellular Tat involves the production of cytokines and expression of cytokine receptors, modulation of survival, proliferation and migration of different cell types, and angiogenic properties.

**B. Tat-Dependent Transcriptional Elongation**

In the last decade, two classes of Tat-associated proteins have been attributed to the Tat-TAR-dependent transactivation: Tat-associated kinases (TAK) and Tat-associated acetyl-transferases. The association of Tat with cellular TAK resulted in a hyperphosphorylation of the RNAPII CTD and proved directly responsible for the enhanced transcriptional processivity of the elongation complex. In addition, it was observed that the transactivation domain of Tat interacted with TAK, which was shown to be identical to the kinase subunit of p-TEFb. In other words, not only NF-kB but also Tat recruits p-TEFb to engender productive elongation (Fig. 4). Although we mentioned (vide supra) that the CDK9 kinase subunit of p-TEFb phosphorylates Ser2 of the CTD of RNAPII, the presence of Tat modifies the substrate specificity of CDK9 enabling the kinase to phosphorylate both Ser2 and Ser5 of the CTD. Consistent with this role, p-TEFb is only able to phosphorylate the RNAPII after phosphorylation by TFIIH and travels with the elongating RNAPII, whereas TFIIH is released from the elongation complex between +14 and +36. Previously, we mentioned the role of DSIF and NELF in transcriptional repression at the early phase of elongation resulting in the generation of short abortive transcripts. Surprisingly, the presence of Tat converts DSIF from a negative to a positive elongation factor by phosphorylation of the hSpt5 subunit of DSIF by p-TEFb. As a result of this transition, DSIF cooperates with Tat in the productive elongation of transcription. Furthermore, not only DSIF is phosphorylated but also NELF becomes phosphorylated by p-TEFb. This causes NELF, that binds to TAR through its RNA recognition motif (RRM), to dissociate from the TAR RNA and relieve transcriptional pausing. Besides the DRB-sensitive CTD kinase activity engendered by the CDK9 subunit, the p-TEFb also consists of a cyclin T subunit, named after its involvement in transcription. Human cyclin T1 (hCycT1) interacts directly with Tat and dramatically enhances its affinity for TAR RNA. Interestingly, the interaction between Tat and hCycT1 requires zinc and a critical cysteine residue on position 261 within the TRM (Tat-TAR recognition motif) of hCycT1. Although murine Cyclin T1 (mCycT1) lacks this C261 residue, it forms also a weak zinc-independent complex with the transactivation domain of Tat but, unlike hCycT1, results in a dramatic reduction in binding efficiency to TAR RNA. Consequently, Tat
function could be specifically inhibited upon overexpression of mCycT1 leading to the formation of an inactive Tat–mCycT1 complex. Thus, the ability of Tat to recruit p-TEFb to TAR RNA not only stimulates transcriptional elongation, but also governs the species specificity of HIV-1. However, the recruitment of p-TEFb to the viral promoter was inhibited by 7SK small nuclear RNA (7SK snRNA) in order to control transcription (Fig. 4). This inhibitory mechanism required “ménage à quatre” 1 (MAQ1) and Hexam-ethylene bisacetamide-induced protein 1 (HEXIM1) to associate with p-TEFb and act as a CDK inhibitor. The HEXIM1 protein interacts directly with 7SK snRNA and the hCycT1 subunit of p-TEFb, by this means competing with Tat for hCycT1 binding. Activation of upstream signaling pathways leads to the abrogation of the interaction of p-TEFb with MAQ1/HEXIM1 and 7SK snRNA. Other CDK inhibitors were based on chemical synthesis with most prominent flavopiridol and R-oscovitine. Both compounds were not only able to inhibit CDK9, but proved also inhibitory to other CDKs involved in transcription such as CDK2 and CDK7. The exact role of CDK2 in Tat-dependent transcription is still unknown, but evidence suggests that CDK2 may function to maintain target-specific phosphorylation of the RNAPII CTD and possibly Tat itself.

Next to the CDK inhibitory mechanism involving MAQ1/HEXIM1 and 7SK snRNA, the formation of the p-TEFb–Tat–TAR ternary complex also requires the relief of two autoinhibitory mechanisms in p-TEFb. Autophosphorylation of CDK9 overcomes the first autoinhibition by creating a favorable p-TEFb conformation and exposing the TRM in hCycT1 for efficient interaction with TAR RNA. TFIIH inhibits CDK9 phosphorylation until it is released from the elongation complex. The second autoinhibition is caused by the intramolecular interaction between the N- and C-terminal regions of hCycT1, which blocks the access of TAR RNA to hCycT1 TRM, and is relieved by interaction of the hCycT1 C-terminal region with the Tat stimulatory factor, Tat-SF1. In addition, the hCycT1–Tat–SF1 interaction may also recruit spliceosomal U small nuclear ribonucleoproteins (snRNPs), which interact with Tat-SF1, so as to elongating RNAPII, and subsequently function in both splicing and transcriptional elongation. Coupling of pre-mRNA splicing and transcription was also seen by two others splicing-associated proteins namely the coactivator of 150 kDa, CA150, and the c-Ski-interacting protein, SKIP. CA150 binds directly to the phosphorylated CTD of RNAPII through its FF repeat motif (so called because of flanking conserved phenylalanine residues) and represses RNAPII transcriptional elongation. Whether this CA150-mediated repression is caused by interaction with the pre-mRNA splicing factor SF1, which has been shown to repress transcription, remains to be clarified. Besides the coupling of transcription and splicing by the CA150–SF1 interaction, CA150 was also able to bind Tat-SF1 through its FF domain. In contrast to CA150, SKIP enhances transcriptional elongation by association with p-TEFb in the p-TEFb-Tat-TAR ternary complex. Furthermore, a direct interaction of SKIP with the spliceosomal protein tri-snRNP110K indicates that only a subset of slicing factors are recruited to the HIV-1 promoter. Besides pre-mRNA splicing, mRNA capping was also found to be coupled with transcriptional elongation. The Tat-TAR-dependent Ser5 phosphorylation of RNAPII CTD is crucial not only in promoting transcription elongation but also in stimulating capping of nascent HIV-1 mRNA. The Tat protein not only regulates transcriptional elongation or post-transcriptional events through RNAPII CTD phosphorylation, but also interferes with the dephosphorylation of RNAPII so as to stimulate transcription. On the one hand, Tat inhibits the CTD phosphatase FCP1 and consequently may alleviate FCP1-mediated pausing of transcription. On the other hand, Tat interacts with the PPP-type protein phosphatase PP1, that also functions as a CTD phosphatase, and augments Tat-mediated transcription.

C. Tat Regulation by Post-Translational Modifications

A second class of Tat-associated proteins that contribute to the Tat-TAR dependent transactivation comprises the Tat-associated acetyltransferases. Tat is known to interact with different
acetyltransferases including the Tat-interactive proteins (Tip60 and Tip110),\textsuperscript{208–210} TAFII250,\textsuperscript{211} the human homolog of yeast GCN5 (hGCN5),\textsuperscript{212} p300/CBP, and P/CAF.\textsuperscript{213–215} P/CAF was able to bind to the cysteine-rich region of non-acetylated Tat and acetylated Lys28 within the transcription-activation domain of Tat. This post-translational modification abrogated the interaction between P/CAF and Tat, but significantly enhanced the recruitment of p-TEFb by Tat.\textsuperscript{216,217} The acetylation site of p300/CBP, as well as hGCN5, has been mapped to Lys50 (and, weakly, to Lys51), a highly conserved amino acid within the TAR RNA-binding domain of Tat. This second post-translational modification leads to the dissociation of pTEFb-Tat from TAR RNA and subsequent binding to the elongating RNAPII.\textsuperscript{212,216,218,219} Both Tat and p-TEFb were able to bind and travel with the elongating RNAPII.\textsuperscript{170,220,221} In addition, acetylation of Tat on Lys50 by p300/CBP also served as a signal for the bromodomain of P/CAF to recruit this transcriptional coactivator to the elongating RNAPII. This results in the formation of a p-TEFb-Tat-P/CAF ternary complex associated with the elongation complex during transcriptional elongation.\textsuperscript{216,217,222,223} The acetylation of Tat (and nuc-1) by p300/CBP could be inhibited by curcumin and resulted in a suppression of Tat-mediated transactivation and HIV replication in cell culture.\textsuperscript{224,225} Both suppressive effects were also found for HR73, an inhibitor of class III deacetylase sirtuin 1 (SIRT1) that is able to deacetylate Lys50 in Tat. This proved that both acetylation and deacetylation are important for the regulation of Tat.\textsuperscript{226}

Other post-translational modifications of Tat that regulate Tat activity have been mapped to Lys 71, that becomes ubiquitinated by the proto-oncoprotein Hdm2, and the arginine-rich motif (amino acids 49–63) which undergoes methylation by protein arginine methyltransferase 6 (PRMT6). Both modifications regulate the transcriptional activity of Tat, positively regulated by modification with ubiquitin and negatively regulated by arginine methylation.\textsuperscript{227,228} As such, it has become increasingly clear that Tat activity needs to be fine-tuned by both positive and negative regulatory mechanisms within cells in order to achieve optimal viral gene expression.

7. \textbf{CONCLUSIONS}

The regulation of HIV-1 transcription is a complex, multistage process that requires the cooperative action of viral and cellular proteins. The position of nuc-1 at the transcription initiation site and its disruption upon transcriptional activation suggests that chromatin plays an essential role in the suppression of HIV-1 expression during latency. Reactivation of the HIV-1 provirus may be mediated by the displacement of HDACs in response to the recruitment of HATs by NF-kB or the viral transactivator Tat. Additionally, productive transcription of the HIV-1 provirus requires the recruitment of CDK9 to the viral promoter by Tat. Although these crucial functions of Tat are indispensable for HIV-1 replication, the implications of Tat reach far beyond both inside and outside the cell. Tat has the unusual property to be released and to enter cells freely without losing activity, enabling the upregulation of numerous genes including HIV-1 gene expression. As such, targeting of Tat protein provides interesting perspectives for therapeutic intervention in HIV infection and offers major possibilities in drug delivery. An important and popular therapeutic approach is based on the interference of Tat interaction with the bulge of TAR RNA. Numerous Tat-TAR inhibitors have been designed and are presented in several classes including peptoids, Tat peptide mimetics, quinolone derivatives, polyamide oligomers, arginine-aminoglycoside conjugates, intercalators, and a large class of small RNA-binding molecules. Another approach to sequester Tat’s function is based on targeting its crucial cofactor CDK9 by CDK inhibitors such as flavopiridol and R-roscovitine. Moreover, R-roscovitine is able to selectively induce apoptosis of HIV-infected cells without viral release opening major perspectives for this class of CDK inhibitors. The Tat-mediated transcription could also be inhibited by curcumin and HR73 which interfere with acetylation and deacetylation of Tat, respectively. This recent approach affecting Tat function emphasize the importance of post-translational modifications in the regulation of Tat. Thus, different anti-HIV strategies based on
directly or indirectly Tat targeting have recently been developed and may provide great promise in drug combination strategies. Once HIV replication is shut down and plasma viral loads have reached undetectable levels upon combination therapy, HIV transcription inhibitors may potentially be able to keep the virus in its dormant state and control the latent HIV-1 reservoir.

ACKNOWLEDGMENTS

We are grateful to Joost Van Durme for excellent graphical assistance and Christophe Pannecouque for critical reading of this manuscript.

REFERENCES

1. Dasgupta P, Saikumar P, Reddy CD, Reddy EP. Myb protein binds to human immunodeficiency virus 1 long terminal repeat (LTR) sequences and transactivates LTR-mediated transcription. Proc Natl Acad Sci USA 1990;87:8090–8094.
2. Seth A, Hodge DR, Thompson DM, Robinson L, Panayiotakis A, Watson DK, Papas TS. ETS family proteins activate transcription from HIV-1 long terminal repeat. AIDS Res Hum Retroviruses 1993;9:1017–1023.
3. Lu YC, Touzjian N, Stenzel M, Dorfman T, Sodroski JG, Haseltine WA. Identification of cis-acting repressive sequences within the negative regulatory element of human immunodeficiency virus type 1. J Virol 1990;64:5226–5229.
4. Shaw JP, Utz PJ, Durand DB, Toole JJ, Emmel EA, Crabtree GR. Identification of a putative regulator of early T cell activation genes. Science 1988;241:202–205.
5. Henderson AJ, Zou X, Calame KL. C/EBP proteins activate transcription from the human immunodeficiency virus type 1 long terminal repeat in macrophages/monocytes. J Virol 1995;69:5337–5344.
6. Franza BR, Rauscher FJ, Josephs SF, Curran T. The Fos complex and Fos-related antigens recognize sequence elements that contain AP-1 binding sites. Science 1988;239:1150–1153.
7. Sheridan PL, Sheline CT, Cannon K, Voz ML, Pazin MJ, Kadonaga JT, Jones KA. Activation of the HIV-1 enhancer by the LEF-1 HMG protein on nucleosome-assembled DNA in vitro. Genes Dev 1995;9:2090–2104.
8. Ghosh H. Glucocorticoid receptor-binding site in the human immunodeficiency virus long terminal repeat. J Virol 1992;66:586–590.
9. Lee MO, Hobbs PD, Zhang XK, Dawson MI, Pfahl M. A synthetic retinoid antagonist inhibits the human immunodeficiency virus type 1 promoter. Proc Natl Acad Sci USA 1994;91:5632–5636.
10. Cooney AJ, Tsai SY, O'Malley BW, Tsai MJ. Chicken ovalbumin upstream promoter transcription factor binds to a negative regulatory region in the human immunodeficiency virus type 1 long terminal repeat. J Virol 1991;65:2853–2860.
11. Lee MO, Dawson MI, Picard N, Hobbs PD, Pfahl M. A novel class of retinoid antagonists and their mechanism of action. J Biol Chem 1996;271:11897–11903.
12. Dickinson LA, Gulizia RJ, Trauger JW, Baird EE, Mosier DE, Gottesfeld JM, Dervan PB. Inhibition of RNA polymerase II transcription in human cells by synthetic DNA-binding ligands. Proc Natl Acad Sci USA 1998;95:12890–12895.
13. Travis A, Amsterdam A, Belanger C, Grosschedl R. LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function. Genes Dev 1991;5:880–894.
14. Giese K, Cox J, Grosschedl R. The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures. Cell 1992;69:185–195.
15. d’Adda di Fagagna F, Marzio G, Gutierrez MI, Kang LY, Falaschi A, Giacca M. Molecular and functional interactions of transcription factor USF with the long terminal repeat of human immunodeficiency virus type 1. J Virol 1995;69:2765–2775.
16. Dickinson LA, Trauger JW, Baird EE, Dervan PB, Graves BJ, Gottesfeld JM. Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-kappaB, and DNA by a designed DNA-binding ligand. J Biol Chem 1999;274:12765–12773.
17. Perkins ND, Agranoff AB, Duckett CS, Nabel GJ. Transcription factor AP-2 regulates human immunodeficiency virus type 1 gene expression. J Virol 1994;68:6820–6823.
18. van Opijnen T, Kamoschinski J, Jeeninga RE, Berkhour B. The human immunodeficiency virus type 1 promoter contains a CATA box instead of a TATA box for optimal transcription and replication. J Virol 2004;78:6883–6890.
19. Harrich D, Garcia J, Wu F, Mitsuyasu R, Gonzalez J, Gaynor R. Role of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeat. J Virol 1989;63:2585–2591.
20. Kato H, Horikoshi M, Roeder RG. Repression of HIV-1 transcription by a cellular protein. Science 1991;251:1476–1479.
21. Parada CA, Yoon JB, Roeder RG. A novel LBP-1-mediated restriction of HIV-1 transcription at the level of elongation in vitro. J Biol Chem 1995;270:2274–2283.
22. Romerio F, Gabriel MN, Margolis DM. Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. J Virol 1997;71:9375–9382.
23. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, Shi Y, Hansen U, Margolis DM. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000;74:6790–6799.
24. He G, Margolis DM. Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol 2002;22:2965–2973.
25. Coull JJ, He G, Melander C, Rucker VC, Dervan PB, Margolis DM. Targeted derepression of the human immunodeficiency virus type 1 long terminal repeat by pyrrole-imidazole polyamides. J Virol 2002;76:12349–12354.
26. Yulisastigui L, Kaur R, Johnson H, Volker J, He G, Hansen U, Margolis D. Mitogen-activated protein kinases regulate LSF occupancy at the human immunodeficiency virus type 1 promoter. J Virol 2005;79:5952–5962.
27. Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol 1995;69:3584–3596.
28. Du H, Roy AL, Roeder RG. Human transcription factor USF stimulates transcription through the initiator elements of the HIV-1 and the Ad-ML promoters. EMBO J 1993;12:501–511.
29. Ratnasabapathy R, Sheldon M, Johal L, Hernandez N. The HIV-1 long terminal repeat contains an unusual element that induces the synthesis of short RNAs from various mRNA and snRNA promoters. Genes Dev 1990;4:2061–2074.
30. Pessler F, Pendergrast PS, Hernandez N. Purification and characterization of FBI-1, a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts. Mol Cell Biol 1997;17:3786–3798.
31. Van Lint C, Amella CA, Emiliani S, John M, Jie T, Verdin E. Transcription factor binding sites downstream of the human immunodeficiency virus type 1 transcription start site are important for virus infectivity. J Virol 1997;71:6113–6127.
32. Mallardo M, Dragonetti E, Baldassarre F, Ambrosino C, Scala G, Quinto I. An NF-kappaB site in the 5′-untranslated leader region of the human immunodeficiency virus type 1 enhances viral expression in response to NF-kappaB-activating stimuli. J Biol Chem 1996;271:20820–20827.
33. Sgarbanti M, Borsetti A, Moscufo N, Bellocchi MC, Ridolfi B, Nappi F, Marsili G, Marziali G, Coccia EM, Ensolii B, Battistini A. Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J Exp Med 2002;195:1359–1370.
34. Marsili G, Remoli AL, Sgarbanti M, Battistini A. Role of acetylases and deacetylase inhibitors in IRF-1-mediated HIV-1 long terminal repeat transcription. Ann NY Acad Sci 2004;1030:636–643.
35. Battistini A, Marsili G, Sgarbanti M, Ensolii B, Hiscott J. IRF regulation of HIV-1 long terminal repeat activity. J Interferon Cytokine Res 2002;22:27–37.
36. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987;326:711–713.
37. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991;10:2247–2258.
38. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med 1992;175:1181–1194.
39. Roederer M, Staal FJ, Raju PA, Ela SW, Herzenberg LA, Herzenberg LA. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci USA 1990;87:4884–4888.
40. Bowie A, O’Neill AJ. Oxidative stress and nuclear factor-kB activation. Biochem Pharmacol 2002;59:13–23.
41. Staal FJ, Roederer M, Herzenberg LA, Herzenberg LA. Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc Natl Acad Sci USA 1990;87:9943–9947.

42. Whiteside ST, Israel A. I kappa B proteins: Structure, function and regulation. Semin Cancer Biol 1997; 8:75–82.

43. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W. IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999;274:30353–30356.

44. Mattioli I, Sebald A, Bucher C, Charles RP, Nakano H, Doi T, Kracht M, Schmitz ML. Transient and selective NF-kappaB p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I kappaB kinase beta and controls the kinetics of p65 nuclear import. J Immunol 2004;172:6336–6344.

45. Lee R, Beauparlant P, Elford H, Ponka P, Hiscott J. Selective inhibition of IkappaB alpha phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds. Virology 1997;234:277–290.

46. Baur A, Harrer T, Peukert M, Jahn G, Kalden JR, Fleckenstein B. Alpha-lipoic acid is an effective inhibitor of human immunodeficiency virus (HIV-1) replication. Klin Wochenschr 1991;69:722–724.

47. Suzuki YJ, Aggarwal BB, Packer L. Alpha-lipoic acid is a potent inhibitor of NF-kappaB activation in human T cells. Biochem Biophys Res Commun 1992;189:1709–1715.

48. Prochaska HJ, Yeh Y, Baron P, Polsky B. Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:3953–3957.

49. Prochaska HJ, Bornmann WG, Baron P, Polsky B. Inhibition of human immunodeficiency virus type 1 replication by 7-methyl-6,8-bis(methylthio)pyrrolo[1,2-α]pyrazine, an in vivo metabolite of oltipraz. Mol Pharmacol 1997;48:15–20.

50. Israel N, Gougerot-Pocidalo MA, Aillet F, Virelizier JL. Redox status of cells influences constitutive or induced NF-kappaB translocation and HIV long terminal repeat activity in human T and monocytic cell lines. J Immunol 1992;149:3386–3393.

51. Kopp E, Ghosh S. Inhibition of NF-κB by sodium salicylate and aspirin. Science 1994;265:956–959.

52. Biswas DK, Dezube BJ, Ahlers CM, Pardee AB. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kappaB A action. J Acquir Immune Defic Syndr 1993;9:787–786.

53. Marquez N, Sancho R, Bedoya LM, Alcami J, Lopez-Perez JL, Feliciano AS, Fiebich BL, Munoz E. Mesulam, a natural occurring 4-phenylcoumarin, inhibits HIV-1 replication by targeting the NF-kappaB pathway. Antiviral Res 2005;66:137–145.

54. Fujiwara M, Okamoto M, Watanabe M, Machida H, Shigeta S, Konno K, Yokota T, Baba M. Acridone derivatives are selective inhibitors of HIV-1 replication in chronically infected cells. Antiviral Res 1999;43:189–199.

55. Hoppe J, Ghosh S. Inhibition of NF-kB by sodium salicylate and aspirin. Science 1994;265:956–959.

56. Sappey C, Boelaert JR, Legrand-Poels S, Forceille C, Favier A, Piette J. Iron chelation decreases NF-kappa B and HIV type 1 activation due to oxidative stress. AIDS Res Hum Retroviruses 1995;11:1049–1061.

57. Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJ, van Asbeck BS. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin. J Infect Dis 2000;181:484–490.

58. Iordanskiy S, Iordanskaya T, Quivy V, Van Lint C, Bukrinsky M. B-oligomer of pertussis toxin inhibits HIV-1 LTR-driven transcription through suppression of NF-kappaB p65 subunit activity. Virology 2002;302:195–206.

59. Lapenta C, Spada M, Santini SM, Racca S, Dorigatti F, Poli G, Belardelli F, Alfano M. Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice. Int Immunol 2005;17:469–475.

60. Beg AA, Ruben SM, Scheinman RI, Haskill S, Rosen CA, Jr., Baldwin AS. I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: A mechanism for cytoplasmic retention. Genes Dev 1992;6:1899–1913.

61. Zhong H, SuYang H, Erdjument-Bromage H, Tempst P, Ghosh S. The transcriptional activity of NF-kappaB is regulated by the IkappaB-associated PKAc subunit through a cyclic AMP-independent mechanism. Cell 1997;89:413–424.

62. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappaB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998;1:661–671.

63. Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc Natl Acad Sci USA 1997;94:2927–2932.

64. Guan H, Hou S, Ricciardi RP. DNA binding of repressor nuclear factor-kappaB p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit. J Biol Chem 2005;280:9957–9962.
65. Zhong H, May MJ, Jimi E, Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol Cell 2002;9:625–636.
66. Ashburner BP, Westerheide SD, Jr., Baldwin AS. The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001;21:7065–7077.
67. Matthews JR, Wakasugi N, Virelizier JL, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-kappaB by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res 1992;20:3821–3830.
68. Matthews JR, Kaszubska W, Turcatti G, Wells TN, Hay RT. Role of cysteine 62 in DNA recognition by the p50 subunit of NF-kappaB. Nucleic Acids Res 1993;21:1727–1734.
69. Nishi T, Shimizu N, Hiramoto M, Sato I, Yamaguchi Y, Hasegawa M, Azawa S, Tanaka H, Kataoka K, Watanabe H, Handa H. Spatial redox regulation of a critical cysteine residue of NF-kappaB in vivo. J Biol Chem 2002;277:44548–44556.
70. Hirota K, Matsui M, Iwata S, Nishiya A, Mori K, Yodoi J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc Natl Acad Sci USA 1997;94:3633–3638.
71. Brennan P, O’Neill LA. 2-mercaptoethanol restores the ability of nuclear factor kappa B (NF-kappaB) to bind DNA in nuclear extracts from interleukin 1-treated cells incubated with pyrollidine dithiocarbamate (PDTC). Evidence for oxidation of glutathione in the mechanism of inhibition of NF-kappa B by PDTC. Biochim J 1996;320:975–981.
72. Toledano MB, Leonard WJ. Modulation of transcription factor NF-kappaB binding activity by oxidation-reduction in vitro. Proc Natl Acad Sci USA 1991;88:4328–4332.
73. Stevens M, Pannecouque C, De Clercq E, Balzarini J. Pyridine N-oxide derivatives inhibit viral transactivation by interfering with NF-kB binding. Biochem Pharmacol 2006;71:1122–1135.
74. Chen F, Lu Y, Castranova V, Rojanasakul Y, Miyahara K, Shizuta Y, Valleyathan V, Shi X, Demers LM. Nitric oxide inhibits HIV Tat-induced NF-kappaB activation. Am J Pathol 1999;155:275–284.
75. Okamoto M, Ono M, Baba M. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaid, cepharanin, in chronically infected monocytic cells. AIDS Res Hum Retroviruses 1998;14:1239–1245.
76. Calzado MA, MacHo A, Lucena C, Munoz E. Hydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoter. Clin Exp Immunol 2000;120:317–323.
77. Yasui H, Butscher W, Cohen M, Spriggs N, Wersto R, Kohn EC, Liotta L, Gardner K. Selective inhibition of mitogen-induced transactivation of the HIV long terminal repeat by carboxyamidotriazole. Calcium influx blockade represses HIV-1 transcriptional activation. J Biol Chem 1997;272:28762–28770.
78. Chen LF, Greene WC. Shaping the nuclear action of NF-kB. Nat Rev Mol Cell Biol 2004;5:392–401.
79. Quivy V, Van Lint C. Diversity of acetylation targets and roles in transcriptional regulation: The human immunodeficiency virus type 1 promoter as a model system. Biochem Pharmacol 2002;64:925–934.
80. Verdin E, Paras P, Jr., Van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993;12:3249–3259.
81. Van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J 1998;10:1112–1120.
82. Sheridan PL, Mayall TP, Verdin E, Jones KA. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev 1997;11:3327–3340.
83. Pazin MJ, Sheridan PL, Cannon K, Cao Z, Keck JG, Kadonaga JT, Jones KA. NF-kappa B-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev 1999;10:37–49.
84. Na SY, Lee SK, Han SJ, Choi HS, Im SY, Lee JW. Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor kappaB-mediated transactivations. J Biol Chem 1998;273:10831–10834.
85. Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, Thanos D, Rosenfeld MG, Glass CK, Collins T. Transcriptional activation by NF-kappaB requires multiple coactivators. Mol Cell Biol 1999;19:6367–6378.
86. Angelov D, Charras M, Seve M, Cote J, Khochbin S, Dimitrov S. Differential remodeling of the HIV-1 nucleosome upon transcription activators and SWI/SNF complex binding. J Mol Biol 2002;320:315–326.
87. Henderson A, Bunce M, Siddon N, Reeves R, Treemethick DJ. High-mobility-group protein I can modulate binding of transcription factors to the US region of the human immunodeficiency virus type 1 proviral promoter. J Virol 2002;74:10523–10534.
88. Henderson A, Holloway A, Reeves R, Treemethick DJ. Recruitment of SWI/SNF to the human immunodeficiency virus type 1 promoter. Mol Cell Biol 2004;24:389–397.
89. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002;108:475–487.
90. Studitsky VM, Walter W, Kireeva M, Kashlev M, Felsenfeld G. Chromatin remodeling by RNA polymerases. Trends Biochem Sci 2004;29:127–135.
91. Kiefer HLB, Hanley TM, Marcello JE, Karthik AG, Viglianti GA. Retinoic acid inhibition of chromatin remodeling at the human immunodeficiency virus type 1 promoter. J Biol Chem 2004;279:43604–43613.
92. Nikolov DB, Burley SK. RNA polymerase II transcription initiation: A structural view. Proc Natl Acad Sci USA 1997;94:15–22.
93. Hahn S. Structure and mechanism of the RNA polymerase II transcription machinery. Nat Struct Mol Biol 2004;11:394–403.
94. Raha T, Cheng SW, Green MR. HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. PLoS Biol 2005;3:e44.
95. Brady J, Kashanchi F. Tat gets the “green” light on transcription initiation. Retrovirology 2005;2:69.
96. Holstege FC, van der Vliet PC, Timmers HT. Opening of an RNA polymerase II promoter occurs in two distinct steps and requires the basal transcription factors IIE and IIF. EMBO J 1996;15:1666–1677.
97. Holstege FC, Fiedler U, Timmers HT. Three transitions in the RNA polymerase II transcription complex during initiation. EMBO J 1997;16:7468–7480.
98. Shiekhattar R, Mermelstein F, Fisher RP, Drapkin R, Wessling HC, Morgan DO, Reinberg D. Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature 1995;374:283–287.
99. Serizawa H, Makela TP, Conaway JW, Conaway RC, Weinberg RA, Young RA. Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature 1995;374:280–282.
100. Moreland RJ, Tirote F, Yan Q, Conaway JW, Egly JM, Conaway RC. A role for the TFIIH XPB DNA helicase in promoter escape by RNA polymerase II. J Biol Chem 1999;274:22127–22130.
101. Spangler L, Wang X, Conaway JW, Conaway RC, Dvir A. TFIIH action in transcription initiation and promoter escape requires distinct regions of downstream promoter DNA. Proc Natl Acad Sci USA 2001;98:5544–5549.
102. West MJ, Lowe AD, Karn J. Activation of human immunodeficiency virus transcription in T cells revisited: NF-kappaB p55 stimulates transcriptional elongation. J Virol 2001;75:8524–8537.
103. Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 2001;8:327–337.
104. McCracken S, Fong N, Rosonina E, Yankulov K, Brothers G, Siderovski D, Hessel A, Foster S, Shuman S, Bentley DL. 5′-Capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II. Genes Dev 1997;11:3306–3318.
105. Cho EJ, Takagi T, Moore CR, Buratowski S. mRNA capping enzyme is recruited to the transcription complex by phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 1997;11:3319–3326.
106. Bentley D. The mRNA assembly line: Transcription and processing machines in the same factory. Curr Opin Cell Biol 2002;14:336–342.
107. Aih SH, Kim M, Buratowski S. Phosphorylation of serine 2 within the RNA polymerase II C-terminal domain couples transcription and 3′ end processing. Mol Cell 2004;13:67–76.
108. Yamaguchi Y, Wada T, Handa H. Interplay between positive and negative elongation factors: Drawing a new view of DRB. Genes Cells 1998;3:9–15.
109. Conaway JW, Shilatifard A, Dvir A, Conaway RC. Control of elongation by RNA polymerase II. Trends Biochem Sci 2000;25:375–380.
110. Yamaguchi Y, Inukai N, Narita T, Wada T, Handa H. Evidence that negative elongation factor represses transcription elongation through binding to a DRB sensitivity-inducing factor/RNA polymerase II complex and RNA. Mol Cell Biol 2002;22:2918–2927.
111. Marshall NF, Peng J, Xie Z, Price DH. Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase. J Biol Chem 1996;271:27176–27183.
112. Price DH. P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 2000;20:2629–2634.
113. Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, Hasegawa J, Handa H. NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell 1999;99:41–51.
114. Wada T, Takagi T, Yamaguchi Y, Watanabe D, Handa H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II dependent transcription in vitro. EMBO J 1998;17:7395–7403.
115. Chambers RS, Dahmus ME. Purification and characterization of a phosphatase from HeLa cells which dephosphorylates the C-terminal domain of RNA polymerase II. J Biol Chem 1994;269:26243–26248.
116. Cho H, Kim TK, Mancebo H, Lane WS, Flores O, Reinberg D. A protein phosphatase functions to recycle RNA polymerase II. Genes Dev 1999;13:1540–1552.
117. Chambers RS, Wang BQ, Burton ZF, Dahmus ME. The activity of COOH-terminal domain phosphatase is regulated by a docking site on RNA polymerase II and by the general transcription factors IIF and IIB. J Biol Chem 1995;270:14962–14969.

118. Dahmus ME. Reversible phosphorylation of the C-terminal domain of RNA polymerase II. J Biol Chem 1996;271:19009–19012.

119. Yeoh M, Lin PS, Dahmus ME, Gill GN. A novel RNA polymerase II C-terminal domain phosphatase that preferentially dephosphorylates serine 5. J Biol Chem 2003;278:26078–26085.

120. Lin PS, Dubois MF, Dahmus ME. TFIIF-associated carboxyl-terminal domain phosphatase dephosphorylates phosphoserines 2 and 5 of RNA polymerase II. J Biol Chem 2002;277:45949–45956.

121. Sheldon M, Ratnasabapathy R, Hernandez N. Characterization of the inducer of short transcripts, a human immunodeficiency virus type I transcriptional element that activates the synthesis of short RNAs. Mol Cell Biol 1993;13:1251–1263.

122. Pendergrast PS, Hernandez N. RNA-targeted activators, but not DNA-targeted activators, repress the synthesis of short transcripts in the human immunodeficiency virus type I long terminal repeat. J Virol 1997;71:910–917.

123. Morrison DJ, Pendergrast PS, Stavropoulos P, Colmenares SU, Kobayashi R, Hernandez N. FBI-1, a factor that binds to the HIV-1 inducer of short transcripts (IST), is a POZ domain protein. Nucleic Acids Res 1999;27:1251–1262.

124. Pendergrast PS, Wang C, Hernandez N, Huang S. FBI-1 can stimulate HIV-1 Tat activity and is targeted to a novel subnuclear domain that includes the Tat-P-TEFb-containing nuclear speckles. Mol Biol Cell 2002, 13:915–929.

125. Selby MJ, Bain ES, Luciw PA, Peterlin BM. Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat. Genes Dev 1989;3:547–558.

126. Dingwall C, Emberg I, Gait MJ, Green SM, Heaphy S, Korn J, Lowe AD, Singh M, Skinner MA. HIV-1 tat protein stimulates transcription by binding to a U-rich bulge in the stem of the TAR RNA structure. EMBO J 1990;9:4145–4153.

127. Weeks, Crothers. RNA recognition by Tat-derived peptides: Interaction in the major groove? Cell 1991; 66:577–588.

128. Churcher MJ, Lamont C, Hamy F, Dingwall C, Green SM, Lowe AD, Butler JG, Gait JM, Korn J. High affinity binding of TAR RNA by the human immunodeficiency virus type-I tat protein requires base-pairs in the RNA stem and amino acid residues flanking the basic region. J Mol Biol 1993;230:90–110.

129. Puglisi JD, Tan R, Calnan BJ, Frankel AD, Williamson JR. Conformation of the TAR RNA-arginine complex by NMR spectroscopy. Science 1992;257:76–80.

130. Aboul-ela F, Korn J, Varani G. The structure of the human immunodeficiency virus type-I TAR RNA reveals principles of RNA recognition by Tat protein. J Mol Biol 1995;253:313–332.

131. Aboul-ela F, Korn J, Varani G. Structure of HIV-1 TAR RNA in the absence of ligands reveals a novel conformation of the trinucleotide bulge. Nucleic Acids Res 1996;24:3974–3981.

132. Pritchard CE, Grasby JA, Hamy F, Zacharek AM, Singh M, Korn J, Gait MJ. Methylphosphonate mapping of phosphates contacts critical for RNA recognition by the human immunodeficiency virus tat and rev proteins. Nucleic Acids Res 1994;22:2592–2600.

133. Hany F, Felder ER, Heizmann G, Lzdins J, Aboul-ela F, Varani G, Korn J, Klimkait T. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 1997; 94:3548–3553.

134. Huang S, Tamilarasu N, Kibler K, Cao H, Ali A, Ping YH, Jeang KT, Rana TM. Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication. J Biol Chem 2003;278:39092–39103.

135. Chevallier I, Wang J, Rabson AB, Stein S, Pooyan S, Stein S, Leibowitz MJ. Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:104–111.

136. Baba M, Okamoto M, Kawamura M, Makino M, Higashida T, Takashi T, Kimura Y, Ikeuchi T, Tetsuka T, Okamoto T. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol Pharmacol 1998;53:1097–1103.

137. Richter S, Parolin C, Gatto B, Del Vecchio C, Brocca-Cofano E, Fravolini A, Palù G, Palumbo M. Inhibition of human immunodeficiency virus type 1 tat-trans-activation-responsive region interaction by an antiviral quinolone derivative. Antimicrob Agents Chemother 2004;48:1895–1899.

138. Mayhood T, Kaushik N, Pandey PK, Kashanchi F, Deng L, Pandey VN. Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Biochemistry 2000;39:11532–11539.
139. Litovchick A, Evdokimov AG, Lapidot A. Arginine-aminoglycoside conjugates that bind to HIV transactivation responsive element RNA in vitro. FEBS Lett 1999;445:73–79.

140. Murchie AI, Davis B, Isel C, Afshar M, Drysdale MJ, Bower J, Potter AJ, Starkey ID, Swarbrick TM, Mirza S, Prescott CD, Vaglio P, Aboul-ela F, Karn J. Structure-based drug design targeting an inactive RNA conformation: Exploiting the flexibility of HIV-1 TAR RNA. J Mol Biol 2004;336:625–638.

141. Darfeuille F, Arzumanov A, Gait MJ, Di Primo C, Toulme JJ. 2'-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry 2002;41:12186–12192.

142. Kolb G, Reigadas S, Boiziazu C, van Aerschot A, Arzumanov A, Gait MJ, Herdevijn P, Toulme JJ. Hexitol nucleic acid-containing aptamers are efficient ligands of HIV-1 TAR RNA. Biochemistry 2005;44:2926–2933.

143. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J Virol 1991;65:6811–6816.

144. Bohjanen PR, Colvin RA, Puttaraju M, Been MD, Garcia-Blanco MA. A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. Nucleic Acids Res 1996;24:3733–3738.

145. Michienzi A, Li S, Ziai JA, Rossi JJ. A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci USA 2002;99:14047–14052.

146. Surabhi RM, Gaynor RB. RNA interference directed against viral and cellular targets inhibits human immunodeficiency Virus Type 1 replication. J Virol 2002;76:12963–12973.

147. Hoque M, Young TM, Lee CG, Serrero G, Mathews MB, Pe’ery T. The growth factor granulin interacts with cyclin T1 and modulates P-TEFb-dependent transcription. Mol Cell Biol 2003;23:1688–1702.

148. Hoque M, Tian B, Mathews MB, Pe’ery T. Granulin and granulin repeats interact with the Tat.P-TEFb complex and inhibit Tat transactivation. J Biol Chem 2005;280:13648–13657.

149. Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J 1995;14:1542–1551.

150. Re MC, Furlini G, Vignoli M, Ramazzotti E, Roderigo G, De Rosa V, Zauli G, Lolli S, Capitani S, La Placa M. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:408–416.

151. Cruikshank WW, Doctrow SR, Falvo MS, Huffman K, Maciaszek J, Viglianti G, Raina J, Kornfeld H, Malfroy B. A lipiddated anti-Tat antibody enters living cells and blocks HIV-1 viral replication. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:193–203.

152. Bai J, Sui J, Zhu RY, Tallarico AS, Gennari F, Zhang D, Marasco WA. Inhibition of tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies. J Biol Chem 2002;278:1433–1442.

153. Rana TM, Jeang KT. Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch Biochem Biophys 1999;365:175–185.

154. Garcia JA, Harrich D, Pearson L, Mitsuyasu R, Gaynor RB. Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J 1988;7:3143–3147.

155. Ruben S, Perkins A, Purcell R, Joung K, Sia R, Burghoff R, Haseltine WA, Rosen CA. Structural and functional characterization of human immunodeficiency virus tat protein. J Virol 1989;63:1–8.

156. Hauber J, Malim MH, Cullen BR. Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol 1989;63:1181–1187.

157. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010–16017.

158. Fittipaldi A, Giacca M. Transcellular protein transduction using the Tat protein of HIV-1. Adv Drug Deliv Rev 2005;57:597–608.

159. Buonaguro L, Barillari G, Chang HK, Bohan CA, Kao V, Morgan R, Gallo RC, Ensoli B. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992;66:7159–7167.

160. Puri RK, Aggarwal BB. Human immunodeficiency virus type 1 tat gene up-regulates interleukin 4 receptors on a human B-lymphoblastoid cell line. Cancer Res 1992;52:3787–3790.

161. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993;67:277–287.
162. Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 1997;159:4077–4083.

163. Albini A, Barillari G, Benelli R, Gallo RC, Ensoli B. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1995;92:4838–4842.

164. Herrmann CH, Rice AP. Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase. Virology 1993;197:601–608.

165. Herrmann CH, Rice AP. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxy-terminal domain of the large subunit of RNA polymerase II: Candidate for a Tat cofactor. J Virol 1995;69:1612–1620.

166. Zhu Y, Pe’ery T, Peng J, Ramanathan Y, Marshall M, Marshall T, Amendt B, Mathews MB, Price DH. Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. Genes Dev 1997;11:2622–2632.

167. Isel C, Karn J. Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxy-terminal domain hyperphosphorylation during transcriptional elongation. J Mol Biol 1999;290:929–941.

168. Kim YK, Bourgeois CF, Isel C, Churcher MJ, Karn J. Phosphorylation of the RNA polymerase II carboxy-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol 2002;22:4622–4637.

169. Zhou M, Halanski MA, Radonovich MF, Khashchani F, Peng J, Price DH, Brady JN. Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxy-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol 2000;20:5077–5086.

170. Ping YH, Rana TM. Tat-associated kinase (P-TEFb): A component of transcription preinitiation and elongation complexes. J Biol Chem 1999;274:7399–7404.

171. Zhou M, Nekhai S, Bharucha DC, Kumar A, Ge H, Price DH, Egly JM, Brady JN. TFIIH inhibits CDK9 phosphorylation during human immunodeficiency virus type I transcription. J Biol Chem 2001;276:44633–44640.

172. Ping YH, Rana TM. DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation. J Biol Chem 2001;276:12951–12958.

173. Kim IB, Sharp PA. Positive transcription elongation factor B phosphorylates hSPT5 and RNA polymerase II carboxy-terminal domain independently of cyclin-dependent kinase-activating kinase. J Biol Chem 2001;276:12317–12323.

174. Bourgeois CF, Kim YK, Churcher MJ, West MJ, Karn J. Spt5 cooperates with human immunodeficiency virus type I Tat by preventing premature RNA release at terminator sequences. Mol Cell Biol 2002;22:1079–1093.

175. Yamaguchi Y, Inukai N, Narita T, Wada T, Handa H. Evidence that negative elongation factor represses transcription elongation through binding to a DRB sensitivity-inducing factor/RNA polymerase II complex and RNA. Mol Cell Biol 2002;22:2918–2927.

176. Fujinaga K, Irwin D, Huang Y, Taube R, Kurosi T, Peterlin BM. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol Cell Biol 2004;24:787–795.

177. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 1998; 92: 451–462.

178. Garber ME, Wei P, Kewal Ramani VN, Mayall TP, Herrmann CH, Rice AP, Littman DR, Jones KA. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev 1998;12:3512–3527.

179. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J 1998;17:7056–7065.

180. Yang Z, Zhu Q, Luo K, Zhou Q. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 2001;414:317–322.

181. Nguyen VT, Kiss T, Michels AA, Bensaude O. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 2001;414:322–325.

182. Michels AA, Nguyen VT, Fraldi A, Labas V, Edwards M, Bonnet F, Lania L, Bensaude O. MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner. Mol Cell Biol 2003; 23:4859–4869.

183. Michels AA, Fraldi A, Li Q, Adamson TE, Bonnet F, Nguyen VT, Sedor SC, Price JP, Price DH, Lania L, Bensaude O. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. EMBO J 2004;23:2608–2619.
184. Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q. Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell 2003;12:971–982.

185. Yik JH, Chen R, Pezda AC, Samford CS, Zhou Q. A human immunodeficiency virus type 1 Tat-like arginine-rich RNA-binding domain is essential for HEXIM1 to inhibit RNA polymerase II transcription through 7SK snRNA-mediated inactivation of P-TEFb. Mol Cell Biol 2004;24:5094–5105.

186. Schulte A, Czudnochowski N, Barboric M, Schonichen A, Blazek D, Peterlin BM, Geyer M. Identification of a cyclin T-binding domain in Hexim1 and biochemical analysis of its binding competition with HIV-1 Tat. J Biol Chem 2005;280:24968–24977.

187. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000;275:28345–28348.

188. Wang D, de la Fuente C, Deng L, Wang L, Zilberman I, Eadie C, Healey M, Stein D, Denny T, Harrison LE, Meijer L, Kashanchi F. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol 2001;75:7266–7279.

189. Agbottah E, de la Fuente C, Nekhai S, Barnett A, Gianella-Borradori A, Kashanchi F. Antiviral activity of CYC202 in HIV-1-infected cells. J Biol Chem 2005;280:3029–3042.

190. Nekhai S, Zhou M, Fernandez A, Lane WS, Lamb NJ, Brady J, Kumar A. HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. Biochem J 2002;364:649–657.

191. Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J Biol Chem 2002;277:33922–33929.

192. Garber ME, Mayall TP, Suess EM, Meisenhelder J, Thompson NE, Jones KA. CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA. Mol Cell Biol 2000;20:6958–6969.

193. Feng YW, Zhou Q. Relief of two built-in autoinhibitory mechanisms in P-TEFb is required for assembly of a multicomponent transcription elongation complex at the human immunodeficiency virus type 1 promoter. Mol Cell Biol 2000;20:5897–5907.

194. Zhou Q, Sharp PA. Tat-SF1: Cofactor for stimulation of transcriptional elongation by HIV-1 Tat. Science 1996;274:605–610.

195. Feng YW, Zhou Q. Stimulatory effect of splicing factors on transcriptional elongation. Nature 2001;414:929–933.

196. Sune C, Hayashi T, Liu Y, Lane WS, Young RA, Garcia-Blanco MA. CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription. Mol Cell Biol 1997;17:6029–6039.

197. Goldstrohm AC, Albrecht TR, Sune C, Bedford MT, Garcia-Blanco MA. The transcription elongation factor CA150 interacts with RNA polymerase II and the pre-mRNA splicing factor SF1. Mol Cell Biol 2001;21:7617–7628.

198. Smith MJ, Kulkarni S, Pawson T. FF domains of CA150 bind transcription and splicing factors through multiple weak interactions. Mol Cell Biol 2004;24:9274–9285.

199. Brès V, Gomes N, Pickle L, Jones KA. A human splicing factor, SKIP, associates with P-TEFb and enhances transcription elongation by HIV-1 Tat. Genes Dev 2005;19:1211–1226.

200. Chiu YL, Coronel E, Ho CK, Shuman S, Rana TM. HIV-1 Tat protein interacts with mammalian capping enzyme and stimulates capping of TAR RNA. J Biol Chem 2001;276:12959–12966.

201. Chiu YL, Ho CK, Saha N, Schwcr B, Shuman S, Rana TM. Tat stimulates cotranscriptional capping of HIV mRNA. Mol Cell Biol 2002;10:585–597.

202. Zhou M, Deng L, Kashanchi F, Brady JN, Shatkin AJ, Kumar A. The Tat/TAR-dependent phosphorylation of RNA polymerase II C-terminal domain stimulates cotranscriptional capping of HIV-1 mRNA. Proc Natl Acad Sci USA 2003;100:12666–12671.

203. Marshall NF, Dahmus GK, Dahmus ME. Regulation of carboxyl-terminal domain phosphatase by HIV-1 tat protein. J Biol Chem 1998;273:31726–31730.

204. Marshall NF, Dahmus ME. C-terminal domain phosphatase sensitivity of RNA polymerase II in early elongation complexes on the HIV-1 and adenovirus 2 major late templates. J Biol Chem 2000;275:32430–32437.

205. Abbott KL, Archambault J, Xiao H, Nguyen BD, Roeder RG, Greenblatt J, Omichinski JG, Legault P. Interactions of the HIV-1 Tat and RAP74 proteins with the RNA polymerase II CTD phosphatase FCP1. Biochemistry 2005;44:2716–2731.

206. Washington K, Ammosova T, Beullens M, Jerebtsova M, Kumar A, Bollen M, Nekhai S. Protein phosphatase-1 dephosphorylates the C-terminal domain of RNA polymerase-II. J Biol Chem 2002;277:40442–40448.
207. Ammosova T, Jerebtsova M, Beullens M, Voloshin Y, Ray PE, Kumar A, Bollen M, Nekhai S. Nuclear protein phosphatase-1 regulates HIV-1 transcription. J Biol Chem 2003;278:32189–32194.
208. Kamine J, Elangovan B, Subramanian T, Coleman D, Chinnadurai G. Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 1996;216:357–366.
209. Yamamoto T, Horikoshi M. Novel substrate specificity of the histone acetyltransferase activity of HIV-1 Tat interacting protein Tip60. J Biol Chem 1997;272:30595–30598.
210. Liu Y, Li J, Kim BO, Pace BS, He JJ. HIV-1 Tat protein-mediated transactivation of the HIV-1 long terminal repeat promoter is potentiated by a novel nuclear Tat-interacting protein of 110 kDa, Tip110. J Biol Chem 2002;277:23854–23863.
211. Weissman JD, Brown JA, Howcroft TK, Hwang J, Chawla A, Roche PA, Schiltz L, Nakatani Y, Singer DS. HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes. Proc Natl Acad Sci USA 1998;95:11601–11606.
212. Col E, Caron C, Seigneurin-Berny D, Gracia J, Favier A, Khochbin S. The histone acetyltransferase, hGCN5, interacts with and acetylates the HIV transactivator. Tat J Biol Chem 2001;276:28179–28184.
213. Benkirane M, Chun RF, Xiao H, Ogryzko VV, Howard BH, Nakatani Y, Jeang KT. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J Biol Chem 1998;273:24898–24905.
214. Marzio G, Tyagi M, Gutierrez MI, Giacca M. HIV-1 Tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc Natl Acad Sci USA 1998;95:13519–13524.
215. Hottiger MO, Nabel GJ. Interaction of human immunodeficiency virus type 1 Tat with the transcriptional coactivators p300 and CREB binding protein. J Virol 1998;72:8252–8256.
216. Kiernan RE, Vanhulle C, Schiltz L, Adam E, Xiao H, Maudoux F, Calomme C, Burny A, Nakatani Y, Jeang KT, Benkirane M, Van Lint C. Acetylation of the HIV-1 Tat protein by p300 is important for its transcriptional activity. EMBO J 1999;18:6106–6118.
217. Brès V, Tagami H, Pélon-pésonè J-M, Loret E, Jeang KT, Nakatani Y, Emiliani S, Benkirane M, Kiernan RE. Differential acetylation of Tat coordinates its interaction with the co-activators cyclin T1 and P/CAF. EMBO J 2002;21:6811–6819.
218. Ott M, Schnolzer M, Garnica J, Fischle W, Emiliani S, Rackwitz HR, Verdin E. HIV-1 tat transcriptional activity is regulated by acetylation. Curr Biol 1999;9:1489–1492.
219. Kaehlcke K, Dorr A, Hetzer-Egger C, Kiermer V, Henklein P, Schneolzer M, Loret E, Cole PA, Verdin E, Ott M. Acetylation of Tat defines a cyclinT1-independent step in HIV transcription. Mol Cell 2003;12:167–176.
220. Cujec TP, Cho H, Maldonado E, Meyer J, Reinberg D, Peterlin BM. The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme. Mol Cell Biol 1997;17:1817–1823.
221. Zhou C, Rana TM. A bimolecular mechanism of HIV-1 Tat protein interaction with RNA polymerase II transcription elongation complexes. J Mol Biol 2002;320:925–942.
222. Mujtaba S, He Y, Zeng L, Farooq A, Carlson JE, Ott M, Verdin E, Zhou MM. Structural basis of lysine-acetylated HIV-1 Tat recognition by P/CAF bromodomain. Mol Cell 2002;9:575–586.
223. Dorr A, Kiermer V, Pedal A, Rackwitz HR, Henklein P, Schubert U, Zhou MM, Verdin E, Ott M. Transcriptional synergy between Tat and P/CAF is dependent on the binding of acetylated Tat to the P/CAF bromodomain. EMBO J 2002;21:2715–2723.
224. Barthelemy S, Vergus L, Moynier M, Guyot D, Labidalle S, Bahraoui E. Curcumin and curcumin derivatives inhibit Tat-mediated transactivation of type 1 human immunodeficiency virus long terminal repeat. Res Virol 1998;149:43–52.
225. Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U, Kundu TK. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004;279:51163–51171.
226. Pagans S, Angelika P, North BJ, Kaehlcke K, Marshall BL, Dorr A, Hetzer-Egger C, Henklein P, Frye R, McNBurney MW, Hruby H, Jung M, Verdin E, Ott M. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS Biol 2005;3:210–220.
227. Brès V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, Tréand C, Emiliani S, Peloponese JM, Jeang KT, Coux O, Scheffner M, Benkirane M. A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat Cell Biol 2003;5:754–761.
228. Boulanger MC, Liang C, Russell RS, Lin R, Bedroom MT, Wainberg MA, Richard S. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol 2005;79:124–131.
Miguel Stevens obtained his degree in Pharmaceutical Sciences (1999) at the University of Ghent (UGent), Belgium, and his Master in Cell Biotechnology (2000) at the Katholieke Universiteit Leuven (K.U.Leuven), Belgium. In 2006, he obtained his Ph.D. as Doctor in Medical Sciences at the Rega Institute for Medical Research.

Erik De Clercq was born in Dendermonde, Belgium, on March 28, 1941. He received his M.D. degree in 1966 and his Ph.D. in 1972 both at the Katholieke Universiteit Leuven (K.U.Leuven) in Belgium. After having spent two years at Stanford University Medical School as a postdoctoral fellow, he returned to the K.U.Leuven Medical School, where he became docent (assistant professor) in 1973, professor in 1975, and full professor in 1977. As of today he is teaching the courses of Cell Biology, Biochemistry, Microbiology and Virology in the first, second and third undergraduate years of the Medical School at the K.U.Leuven and K.U.Leuven Campus Kortrijk. Prof. E. De Clercq served as chairman of the Department of Microbiology from 1986-1991. Since 1999 he is again serving as chairman of the Department of Microbiology and Immunology. In 1985, he became President of the Rega Foundation and, in 1986, Chairman of the Board of the Rega Institute for Medical Research, two positions which he still holds. He is a titular member of the Belgian Royal Academy of Medicine and the Academia Europaea, and has also held the Prof. P. De Somer Chair of Microbiology at the K.U.Leuven. Prof. De Clercq’s scientific achievements are in the antiviral chemotherapy field, and, in particular, the development of new antiviral agents for the treatment of various viral infections, including AIDS. He has (co)-discovered a number of antiviral drugs, currently used in the treatment of various virus infections, such as herpes simplex (valaciclovir), herpes zoster (brivudin), CMV (cytomegalovirus) infections (cidofovir), HBV (hepatitis B virus) infections (adefovir), and HIV infections (AIDS) (tenofovir disoproxil fumarate, marketed as Viread™, and, in combination with emtricitabine, as Truvada™).

Jan Balzarini obtained his degree in Master in Biological Sciences (1975) and his degree as Bio-Engineer in Biochemistry and Microbiology (1977) at the Katholieke Universiteit Leuven (K.U.Leuven), Belgium. In 1984, he obtained his Ph.D. as Doctor in the Bioengineering at the Rega Institute for Medical Research, and received a tenured research position at the K.U.Leuven. After a post-doctoral stay at the National Institutes of Health, Jan Balzarini became, respectively, assistant-, associate- and eventually full professor of Virology and Chemotherapy at the Faculty of Medicine of the K.U.Leuven. His research projects are focussed on combined gene/chemotherapy of cancer, nucleoside kinases, antiviral chemotherapy (with a focus on AIDS, influenza and coronaviruses), mechanism of action of antiviral/anticancer drugs and molecular mechanisms of drug resistance. Jan Balzarini has received several awards, including the International René-Descartes Prize-2001 of the European Commission. He is on the Board of Directors of the International Society of Antiviral Research (ISAR) and the Rega Foundation of the K.U.Leuven.